Knowledge Hub

Global Market Provides Competitive Pipeline Landscape of PD-1 and PD-L1 Inhibitors Market Analysis, 2017

Press Release   •   Feb 23, 2017 05:25 EST

DelveInsights, PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

View Report @ http://www.marketresearchreports.biz/analysis/964541

Scope

  • The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for PD and PD-L1 inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Get Sample Copy Of This Report At :

http://www.marketresearchreports.biz/sample/sample/964541

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Content :

Introduction

Executive Summary

Programmed Death 1 (PD-1)

Programmed Death Ligand 1 (PD-L1)

Role of PD-1 and PD-L1 pathways

MOA of PD-1 and PD-L1 inhibitors

Significance of PD-1 and PD-L1 inhibitors

PD-1 and PD-L1 Active Therapy Areas & Epidemiology

Metastatic Renal Cell Carcinoma

Squamous Cell Carcinomas of the Head and Neck

Metastatic Colorectal Cancer

Non-Small Cell lung cancer

Biomarkers - PD-1 and PD-L1 inhibitors

Market Overview

Comparative Analysis of Pipeline &Marketed Drugs

Marketed Product of PD-1 and PD-L1 drugs Overview

Marketed Drug Candidate Profiles

Pembrolizumab

Nivolumab

Atezolizumab

Marketed Drugs Sales

Details of Patent Expiry of Marketed Drugs

Current and Future Market for PD and PD-L1 inhibitors

Challenges and Barriers associated with use of PD and PD-L1 inhibitors

PD-1/PD-L1Combinations Creating Boom

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.